Amicus Therapeutics (FOLD) has disclosed a new risk, in the Regulation category.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amicus Therapeutics faces potential business risks due to possible significant changes in U.S. laws or policies, particularly those affecting international trade and regulatory pathways. As a biotechnology company focused on rare disease treatments, Amicus is vulnerable to alterations in trade policies and tariffs, along with any ensuing international reactions that could disrupt their product sourcing and distribution. The evolving political landscape, including potential reforms under the new presidential administration, may impact the FDA’s authority and lead to increased tariffs, particularly affecting critical suppliers like the PRC. Such developments could raise production costs and complicate global medicine delivery, adversely affecting Amicus’s business and financial outcomes.
Overall, Wall Street has a Moderate Buy consensus rating on FOLD stock based on 7 Buys and 3 Holds.
To learn more about Amicus Therapeutics’ risk factors, click here.